Literature DB >> 1707985

Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates.

P Horal1, B Svennerholm, S Jeansson, L Rymo, W W Hall, A Vahlne.   

Abstract

Immunoreactive regions of human immunodeficiency virus type 1 (HIV-1) gp41 were mapped by reacting HIV-1 antibody-positive human sera with overlapping synthetic peptides which covered the transmembrane protein. Three immunoreactive domains were identified, and five different and partially overlapping epitopes recognized by HIV-1-positive human sera were found within one immunodominant region. The effect on antibody recognition after single amino acid substitutions within one defined epitope was also studied. The reactivity of various HIV-1-positive sera to synthetic peptides with amino acid substitutions representing known isolates suggests an important substitution in the major epitope of African HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707985      PMCID: PMC240636     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

Review 2.  Markers for progression in HIV infection.

Authors:  J M Lange; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1989       Impact factor: 4.177

3.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

Review 4.  HIV antibodies and vaccine design.

Authors:  D P Bolognesi
Journal:  AIDS       Date:  1989       Impact factor: 4.177

Review 5.  Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts.

Authors:  J Goudsmit
Journal:  AIDS       Date:  1988       Impact factor: 4.177

6.  Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection.

Authors:  A Närvänen; M Korkolainen; J Suni; J Korpela; S Kontio; P Partanen; A Vaheri; M L Huhtala
Journal:  J Med Virol       Date:  1988-10       Impact factor: 2.327

7.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

8.  Discrimination between antibodies to HIV and to related retroviruses using site-directed serology.

Authors:  E Norrby; G Biberfeld; F Chiodi; A von Gegerfeldt; A Nauclér; E Parks; R Lerner
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

9.  Comparison of detection of antibody to the acquired immune deficiency syndrome virus by enzyme immunoassay, immunofluorescence, and Western blot methods.

Authors:  D Gallo; J L Diggs; G R Shell; P J Dailey; M N Hoffman; J L Riggs
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

10.  The chemistry of site-directed serology for HIV infections.

Authors:  E Norrby; G Biberfeld; P R Johnson; D E Parks; R A Houghten; R A Lerner
Journal:  AIDS Res Hum Retroviruses       Date:  1989-10       Impact factor: 2.205

View more
  14 in total

1.  Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection.

Authors:  J Dorn; S Masciotra; C Yang; R Downing; B Biryahwaho; T D Mastro; J Nkengasong; D Pieniazek; M A Rayfield; D J Hu; R B Lal
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Authors:  Catherine M Finnegan; Werner Berg; George K Lewis; Anthony L DeVico
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Inexpensive designer antigen for anti-HIV antibody detection with high sensitivity and specificity.

Authors:  Sheikh M Talha; Teppo Salminen; Deepti A Chugh; Sathyamangalam Swaminathan; Tero Soukka; Kim Pettersson; Navin Khanna
Journal:  Clin Vaccine Immunol       Date:  2010-01-20

6.  The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.

Authors:  M Urban; W Britt; M Mach
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.

Authors:  G Pancino; C Chappey; W Saurin; P Sonigo
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.

Authors:  A Vahlne; P Horal; K Eriksson; S Jeansson; L Rymo; K G Hedström; C Czerkinsky; J Holmgren; B Svennerholm
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

9.  Escherichia coli-expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen.

Authors:  Sheikh M Talha; Satish Kumar Nemani; Teppo Salminen; Sushil Kumar; Sathyamangalam Swaminathan; Tero Soukka; Kim Pettersson; Navin Khanna
Journal:  BMC Infect Dis       Date:  2012-11-27       Impact factor: 3.090

10.  Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.

Authors:  Adam Penn-Nicholson; Dong P Han; Soon J Kim; Hanna Park; Rais Ansari; David C Montefiori; Michael W Cho
Journal:  Virology       Date:  2007-12-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.